{"pmid":32502524,"pmcid":"PMC7264941","title":"Tocilizumab administration in a refractory case of COVID-19.","text":["Tocilizumab administration in a refractory case of COVID-19.","Novel coronavirus (COVID-19) pneumonia as a pandemic disease leads to acute respiratory distress syndrome (ARDS), acute cardiac injury, multi organ failure, and shock. In the absence of specific treatment for COVID-19, there is an urgent need to find the alternative treatments to manage this pandemic. Pathophysiological studies have demonstrated the role of inflammatory mediators in COVID-19 pneumonia. It appears that imbalances between inflammatory and anti-inflammatory cytokines are the probable underlying mechanism. Since, there is no specific treatment for the inflammatory phase of COVID-19 pneumonia, consideration of treatments, such as tocilizumab, as salvage therapy is necessary. Here, we reported a challenging case of COVID-19 who was successfully treated with tocilizumab.","Int J Antimicrob Agents","Dastan, Farzaneh","Nadji, Seyed Alireza","Saffaei, Ali","Tabarsi, Payam","32502524"],"abstract":["Novel coronavirus (COVID-19) pneumonia as a pandemic disease leads to acute respiratory distress syndrome (ARDS), acute cardiac injury, multi organ failure, and shock. In the absence of specific treatment for COVID-19, there is an urgent need to find the alternative treatments to manage this pandemic. Pathophysiological studies have demonstrated the role of inflammatory mediators in COVID-19 pneumonia. It appears that imbalances between inflammatory and anti-inflammatory cytokines are the probable underlying mechanism. Since, there is no specific treatment for the inflammatory phase of COVID-19 pneumonia, consideration of treatments, such as tocilizumab, as salvage therapy is necessary. Here, we reported a challenging case of COVID-19 who was successfully treated with tocilizumab."],"journal":"Int J Antimicrob Agents","authors":["Dastan, Farzaneh","Nadji, Seyed Alireza","Saffaei, Ali","Tabarsi, Payam"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32502524","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.ijantimicag.2020.106043","keywords":["acute respiratory distress syndrome","covid-19","coronavirus","interleukin-6, tocilizumab"],"e_drugs":["tocilizumab"],"topics":["Case Report"],"weight":1,"_version_":1668890966424027136,"score":9.490897,"similar":[{"pmid":32359210,"title":"Clinical Course of COVID-19 in a Liver Transplant Recipient on Hemodialysis and Response to Tocilizumab Therapy: A Case Report.","text":["Clinical Course of COVID-19 in a Liver Transplant Recipient on Hemodialysis and Response to Tocilizumab Therapy: A Case Report.","The novel coronavirus disease 2019 (COVID-19) is a highly infectious and rapidly spreading disease. There are limited published data on the epidemiology and outcomes of COVID-19 infection among organ transplant recipients. After initial flulike symptoms, progression to an inflammatory phase may occur, characterized by cytokine release rapidly leading to respiratory and multiorgan failure. We report the clinical course and management of a liver transplant recipient on hemodialysis, who presented with COVID-19 pneumonia, and despite completing a 5-day course of hydroxychloroquine, later developed marked inflammatory manifestations with rapid improvement after administration of off-label, single-dose tocilizumab. We also highlight the role of lung ultrasonography in early diagnosis of the inflammatory phase of COVID-19. Future investigation of the effects of immunomodulators among transplant recipients with COVID-19 infection will be important.","Am J Transplant","Hammami, Muhammad Baraa","Garibaldi, Brian","Shah, Pali","Liu, Gigi","Jain, Tania","Chen, Po-Hung","Kim, Amy K","Avdic, Edina","Petty, Brent","Strout, Sara","Fine, Derek M","Niranjan-Azadi, Ashwini","Garneau, William M","Cameron, Andrew M","Monroy Trujillo, Jose M","Gurakar, Ahmet","Avery, Robin","32359210"],"abstract":["The novel coronavirus disease 2019 (COVID-19) is a highly infectious and rapidly spreading disease. There are limited published data on the epidemiology and outcomes of COVID-19 infection among organ transplant recipients. After initial flulike symptoms, progression to an inflammatory phase may occur, characterized by cytokine release rapidly leading to respiratory and multiorgan failure. We report the clinical course and management of a liver transplant recipient on hemodialysis, who presented with COVID-19 pneumonia, and despite completing a 5-day course of hydroxychloroquine, later developed marked inflammatory manifestations with rapid improvement after administration of off-label, single-dose tocilizumab. We also highlight the role of lung ultrasonography in early diagnosis of the inflammatory phase of COVID-19. Future investigation of the effects of immunomodulators among transplant recipients with COVID-19 infection will be important."],"journal":"Am J Transplant","authors":["Hammami, Muhammad Baraa","Garibaldi, Brian","Shah, Pali","Liu, Gigi","Jain, Tania","Chen, Po-Hung","Kim, Amy K","Avdic, Edina","Petty, Brent","Strout, Sara","Fine, Derek M","Niranjan-Azadi, Ashwini","Garneau, William M","Cameron, Andrew M","Monroy Trujillo, Jose M","Gurakar, Ahmet","Avery, Robin"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32359210","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/ajt.15985","locations":["multiorgan"],"e_drugs":["Hydroxychloroquine","tocilizumab"],"topics":["Case Report"],"weight":1,"_version_":1666138495311151104,"score":176.01233},{"pmid":32290839,"pmcid":"PMC7154566","title":"Why tocilizumab could be an effective treatment for severe COVID-19?","text":["Why tocilizumab could be an effective treatment for severe COVID-19?","A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was identified in December 2019 (COVID-19), spread rapidly and has become a world-wide public health challenge. About 25% of COVID-19 patients experienced severe complications including acute respiratory distress syndrome (ARDS), and even progressed into an intensive care unit (ICU) admission and died. The exploration for the mortality causes and advancing novel therapeutic development of severe COVID-19 is crucial at the moment. The biopsy samples analysis at autopsy suggested that increased alveolar exudate caused by aberrant host immune response and inflammatory cytokine storm probably impedes alveolar gas exchange and contributes to the high mortality of severe COVID-19 patients. Our research has identified that pathogenic T cells and inflammatory monocytes incite inflammatory storm with large amount of interleukin 6, therefore monoclonal antibody that targets the IL-6 pathways may potentially curb inflammatory storm. Moreover, Tocilizumab treatment that blocking IL-6 receptors showed inspiring clinical results including temperature returned to normal quickly and respiratory function improved. Therefore, we suggest that Tocilizumab is an effective treatment in severe patients of COVID-19 to calm the inflammatory storm and reduce mortality.","J Transl Med","Fu, Binqing","Xu, Xiaoling","Wei, Haiming","32290839"],"abstract":["A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was identified in December 2019 (COVID-19), spread rapidly and has become a world-wide public health challenge. About 25% of COVID-19 patients experienced severe complications including acute respiratory distress syndrome (ARDS), and even progressed into an intensive care unit (ICU) admission and died. The exploration for the mortality causes and advancing novel therapeutic development of severe COVID-19 is crucial at the moment. The biopsy samples analysis at autopsy suggested that increased alveolar exudate caused by aberrant host immune response and inflammatory cytokine storm probably impedes alveolar gas exchange and contributes to the high mortality of severe COVID-19 patients. Our research has identified that pathogenic T cells and inflammatory monocytes incite inflammatory storm with large amount of interleukin 6, therefore monoclonal antibody that targets the IL-6 pathways may potentially curb inflammatory storm. Moreover, Tocilizumab treatment that blocking IL-6 receptors showed inspiring clinical results including temperature returned to normal quickly and respiratory function improved. Therefore, we suggest that Tocilizumab is an effective treatment in severe patients of COVID-19 to calm the inflammatory storm and reduce mortality."],"journal":"J Transl Med","authors":["Fu, Binqing","Xu, Xiaoling","Wei, Haiming"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32290839","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1186/s12967-020-02339-3","keywords":["acute respiratory distress syndrome (ards)","covid-19","il-6","inflammatory storm","sars-cov-2","tocilizumab"],"link_comment_in":"32290847","e_drugs":["tocilizumab"],"topics":["Treatment"],"weight":1,"_version_":1666138494423007232,"score":171.36984},{"pmid":32360516,"pmcid":"PMC7189192","title":"The first case of COVID-19 treated with the complement C3 inhibitor AMY-101.","text":["The first case of COVID-19 treated with the complement C3 inhibitor AMY-101.","Acute respiratory distress syndrome (ARDS) is a devastating clinical manifestation of COVID-19 pneumonia and is mainly based on an immune-driven pathology. Mounting evidence suggests that COVID-19 is fueled by a maladaptive host inflammatory response that involves excessive activation of innate immune pathways. While a \"cytokine storm\" involving IL-6 and other cytokines has been documented, complement C3 activation has been implicated as an initial effector mechanism that exacerbates lung injury in preclinical models of SARS-CoV infection. C3-targeted intervention may provide broader therapeutic control of complement-mediated inflammatory damage in COVID-19 patients. Herein, we report the clinical course of a patient with severe ARDS due to COVID-19 pneumonia who was safely and successfully treated with the compstatin-based complement C3 inhibitor AMY-101.","Clin Immunol","Mastaglio, Sara","Ruggeri, Annalisa","Risitano, Antonio M","Angelillo, Piera","Yancopoulou, Despina","Mastellos, Dimitrios C","Huber-Lang, Markus","Piemontese, Simona","Assanelli, Andrea","Garlanda, Cecilia","Lambris, John D","Ciceri, Fabio","32360516"],"abstract":["Acute respiratory distress syndrome (ARDS) is a devastating clinical manifestation of COVID-19 pneumonia and is mainly based on an immune-driven pathology. Mounting evidence suggests that COVID-19 is fueled by a maladaptive host inflammatory response that involves excessive activation of innate immune pathways. While a \"cytokine storm\" involving IL-6 and other cytokines has been documented, complement C3 activation has been implicated as an initial effector mechanism that exacerbates lung injury in preclinical models of SARS-CoV infection. C3-targeted intervention may provide broader therapeutic control of complement-mediated inflammatory damage in COVID-19 patients. Herein, we report the clinical course of a patient with severe ARDS due to COVID-19 pneumonia who was safely and successfully treated with the compstatin-based complement C3 inhibitor AMY-101."],"journal":"Clin Immunol","authors":["Mastaglio, Sara","Ruggeri, Annalisa","Risitano, Antonio M","Angelillo, Piera","Yancopoulou, Despina","Mastellos, Dimitrios C","Huber-Lang, Markus","Piemontese, Simona","Assanelli, Andrea","Garlanda, Cecilia","Lambris, John D","Ciceri, Fabio"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360516","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.clim.2020.108450","topics":["Case Report"],"weight":1,"_version_":1666138495520866304,"score":170.71274},{"pmid":32421092,"pmcid":"PMC7224649","title":"SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc.","text":["SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc.","Since the outbreak of COVID-19 many studies have been published showing possible therapies, here the author discusses the end of stage disease related drugs, like Tocilizumab which is currently being used in ARDS patients. In some patients, disease progression leads to an enormous secretion of cytokines, known as cytokine storm, among those cytokines IL-6 plays an important role. Here the author shows how IL-6 has both pro and anti-inflammatory properties, depending on the pathway of transduction: soluble (trans-signaling) or membrane-related (classic signaling), and suggests how targeting only the pro-inflammatory pathway, with SGP130Fc, could be a better option then targeting them both. Other possible IL-6 pathway inhibitors such as Ruxolitinib and Baricinitib are then analyzed, underlying how they lack the benefit of targeting only the pro-inflammatory pathway.","Cytokine X","Magro, Giuseppe","32421092"],"abstract":["Since the outbreak of COVID-19 many studies have been published showing possible therapies, here the author discusses the end of stage disease related drugs, like Tocilizumab which is currently being used in ARDS patients. In some patients, disease progression leads to an enormous secretion of cytokines, known as cytokine storm, among those cytokines IL-6 plays an important role. Here the author shows how IL-6 has both pro and anti-inflammatory properties, depending on the pathway of transduction: soluble (trans-signaling) or membrane-related (classic signaling), and suggests how targeting only the pro-inflammatory pathway, with SGP130Fc, could be a better option then targeting them both. Other possible IL-6 pathway inhibitors such as Ruxolitinib and Baricinitib are then analyzed, underlying how they lack the benefit of targeting only the pro-inflammatory pathway."],"journal":"Cytokine X","authors":["Magro, Giuseppe"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32421092","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.cytox.2020.100029","keywords":["baricitinib","covid-19","il-6","il-6 trans-signaling","interleukin-6","ruxolitinib","sars-cov-1","sars-cov-2","sgp130fc","tocilizumab","coronavirus","coronaviruses","drugs","strategies","targets","therapies"],"e_drugs":["INCB018424","tocilizumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667159284554661888,"score":157.74214},{"pmid":32373721,"pmcid":"PMC7193092","title":"Low dose lung radiotherapy for COVID-19 pneumonia. The rationale for a cost-effective anti-inflammatory treatment.","text":["Low dose lung radiotherapy for COVID-19 pneumonia. The rationale for a cost-effective anti-inflammatory treatment.","The COVID-19 pandemia is affecting people worldwide. Most of the patients suffered of a respiratory disease that will progress to an acute respiratory distress syndrome (ARDS). SARS-CoV-2 pneumonia severely ill patients, develop a systemic inflammatory response with a Cytokine Release Syndrome (CRS), that is characterized by a sudden increase in several pro-inflammatory cytokines, mainly IL-1, IL-6 and TNF-alfa by activated macrophages (M1 phenotype). Blocking IL-6 with tocilizumab and using respirator equipment seems to be a very important issue in this (SARS-CoV-2) pneumonia, but not all patients are referred to such treatments. Low dose radiotherapy (0,5 Gy), is an evidence-based anti-inflammatory treatment, that could modify the immune landscape in the lung affected of SARS-CoV-2 pneumonia, through macrophages polarization to alternatively activated Macrophages (M2 phenotype). Radiation-induced cancer risk could be assumed due to the very low dose used, the advanced age of the patients and the life-threatening condition of SARS-Cov2 pneumonia. LDRT is a cost-effective non-toxic treatment already available in most general hospitals. This fact allows that it would be used for the large number of patients that will suffer this disease, and that would not receive specific anti-IL-6 treatments in ICUs in low and middle income countries.","Clin Transl Radiat Oncol","Lara, Pedro C","Burgos, Javier","Macias, David","32373721"],"abstract":["The COVID-19 pandemia is affecting people worldwide. Most of the patients suffered of a respiratory disease that will progress to an acute respiratory distress syndrome (ARDS). SARS-CoV-2 pneumonia severely ill patients, develop a systemic inflammatory response with a Cytokine Release Syndrome (CRS), that is characterized by a sudden increase in several pro-inflammatory cytokines, mainly IL-1, IL-6 and TNF-alfa by activated macrophages (M1 phenotype). Blocking IL-6 with tocilizumab and using respirator equipment seems to be a very important issue in this (SARS-CoV-2) pneumonia, but not all patients are referred to such treatments. Low dose radiotherapy (0,5 Gy), is an evidence-based anti-inflammatory treatment, that could modify the immune landscape in the lung affected of SARS-CoV-2 pneumonia, through macrophages polarization to alternatively activated Macrophages (M2 phenotype). Radiation-induced cancer risk could be assumed due to the very low dose used, the advanced age of the patients and the life-threatening condition of SARS-Cov2 pneumonia. LDRT is a cost-effective non-toxic treatment already available in most general hospitals. This fact allows that it would be used for the large number of patients that will suffer this disease, and that would not receive specific anti-IL-6 treatments in ICUs in low and middle income countries."],"journal":"Clin Transl Radiat Oncol","authors":["Lara, Pedro C","Burgos, Javier","Macias, David"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32373721","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.ctro.2020.04.006","keywords":["covid-19 pneumonia","low dose radiotherapy","lung"],"e_drugs":["tocilizumab"],"topics":["Treatment"],"weight":1,"_version_":1666138496456196097,"score":155.51738}]}